➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Express Scripts
Merck
Moodys
Dow

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 8,691,231

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,691,231
Title:Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
Inventor(s): Bukhalid; Raghida (Melrose, MA), Nielsen; Ulrik (Quincy, MA), Werner; Shannon (Belmont, MA), Kearns; Jeffrey David (Arlington, MA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/488,270
Patent Claims:see list of patent claims

Details for Patent 8,691,231

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2031-06-03 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2031-06-03 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2031-06-03 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2031-06-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKinsey
Dow
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.